A 探花直播 of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a 拢2.14 million seed funding round.
A 探花直播 of Cambridge spin-out company from the Cavendish Laboratory, combines materials engineering and cell biology to help biopharma companies make better medicines, faster. It announced today that it has closed a 拢2.14 million seed funding round.
探花直播funding will support the commercial development of Semarion鈥檚 SemaCyte庐 cell assaying platform. It will also enable further expansion of the team, as Semarion recruits scientists and engineers, and establishes additional research partnerships with biopharma partners for bespoke solutions to cell screening challenges.
SemaCytes, developed by Semarion, are a novel class of cell carrier materials, created using microchip fabrication technologies, nanomagnetism听and smart materials. By facilitating workflow automation, assay miniaturisation听and cell barcoding, this technology improves the quality and reproducibility of cell screening data while reducing the time and cost of drug discovery workflows.
Semarion was co-founded at the Cavendish Laboratory in 2018 by Jeroen Verheyen (CEO), Tarun Vemulkar (CTO), and Professor Russell Cowburn. Verheyen鈥檚 background in cell model development and Vemulkar鈥檚 experience in advanced materials and microfabrication drive Semarion鈥檚 vision to address foundational bottlenecks in drug discovery by integrating expertise across disciplines. Previously, the company received pre-seed funding and business support from Cambridge-based healthcare accelerator, , which supported the transition of the company out of the 探花直播.
This investment round was led by Parkwalk Advisors, with the 探花直播 of Cambridge Seed Funds, Martlet Capital, and angel investors also contributing.
Jeroen Verheyen, Co-Founder & CEO, Semarion, said: 鈥淭his is a crucial step towards the commercialisation of our SemaCyte cell assaying platform. We were excited to see our product testers appreciate its truly unique feature. We aim to keep working closely with biopharma partners to address their unmet cell screening needs. I would like to thank all our investors and supporters for believing in the Semarion team and the SemaCyte technology.鈥
Dr Del Trezise, Advisor and Non-Executive director at Semarion said: 鈥淥ur investors have identified the potential of Semarion鈥檚 technology, which is uniquely positioned to address a significant market opportunity and revolutionise drug discovery approaches. I look forward to working with the team to support the Company as it progresses to the next stage of commercial and scientific expansion." 听听
探花直播text in this work is licensed under a . Images, including our videos, are Copyright 漏 探花直播 of Cambridge and licensors/contributors as identified.听 All rights reserved. We make our image and video content available in a number of ways 鈥 as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.
